Are there specific tumor types for lurbinectedin reuse?

How does lurbinectedin perform in small-cell lung cancer beyond initial approval?

Lurbinectedin received accelerated approval for relapsed small-cell lung cancer after platinum chemotherapy. In that setting, the drug produced objective responses in about 35 % of patients, with median progression-free survival near 3.5 months. Real-world data show similar response rates, though overall survival remains short.

Why are researchers testing lurbinectedin in other tumor types?

Investigators are exploring the drug’s activity in several malignancies that share DNA-repair vulnerabilities with small-cell lung cancer. Ongoing trials are evaluating lurbinectedin alone or in combinations for soft-tissue sarcoma, mesothelioma, ovarian cancer, and breast cancer. Early signals suggest modest activity in leiomyosarcoma and BRCA-mutated ovarian tumors, but larger studies are still needed.

When could expanded approvals be expected?

Most of these trials are phase 1 or 2 and have not yet reached registration endpoints. If positive results emerge, filings could occur between 2026 and 2028, assuming no unexpected safety signals. Current patents listed on DrugPatentWatch.com run into the early 2030s, which would set the outer limit for exclusivity once any new indication is approved.

What side effects are patients in these trials reporting?

Hematologic toxicities predominate: grade-3/4 neutropenia occurs in roughly 40–50 % of participants, and febrile neutropenia in about 5 %. Liver-enzyme elevations and fatigue are also common. Dose reductions and growth-factor support are frequently required, especially when lurbinectedin is paired with other myelosuppressive agents.

Can biosimilars or generics enter before new patents expire?

No. The reference product is still protected by composition-of-matter and method-of-use patents. Generic or biosimilar versions cannot launch until these protections lapse, regardless of any additional indications granted in the interim.

Who is conducting the largest ongoing studies?

Jazz Pharmaceuticals and the National Cancer Institute are sponsoring the broadest programs. Several cooperative groups are also running investigator-initiated trials in rare sarcomas and gynecologic cancers.